UPClytics
English
Sign inSign up
Analytics2,692Cases1,785Decisions257Judges1,851Parties459Firms

Cases

Workhorse listing across all UPC cases. Filters apply across tabs.

CasesDecisionsJudgesPartiesFirmsAnalytics
DateCaseDivisionActionMotionOutcomeSummary
2025-04-22UPC_APP_17607/2025Milan CDApplication Rop 265ProceduralWithdrawnThe Milan Central Division allowed Pfizer's withdrawal of both the revocation action (ACT_45928/2024) and the counterclaim for revocation (CC_60908/2024) against GlaxoSmithKline Biologicals SA concerning EP 4 183 412 (RSV vaccine patent), with GSK's consent and without a cost decision; 60% of court fees were reimbursed to Pfizer.
2025-04-22UPC_APP_16366/2025Milan CDApplication Rop 265ProceduralWithdrawnMilan Central Division procedural order granting Pfizer's application to withdraw a revocation action against GlaxoSmithKline Biologicals SA concerning EP 4 183 412 (RSV F protein vaccine patent), and a separately filed counterclaim for revocation in parallel Düsseldorf infringement proceedings (which had been referred to the Central Division). Pfizer and Glaxo had each filed applications to amend the patent; both revocation actions were withdrawn by Pfizer prior to closure of the written procedure. The court also ordered 60% reimbursement of court fees and confirmed each party bears its own costs.
2025-04-22UPC_APP_17784/2025Milan CDApplication Rop 265ProceduralWithdrawnOrder by Milan Central Division (UPC_CFI_687/2024, 22 April 2025) permitting Pfizer's withdrawal of the revocation action and counterclaim for revocation against GlaxoSmithKline's EP 4 183 412 (RSV F protein vaccine), and permitting GlaxoSmithKline to withdraw its patent amendment application. 60% court fee reimbursement was granted; each party bears its own costs.
2025-04-22UPC_CFI_476/2024Milan CDApplication Rop 265—WithdrawnMilan Central Division allowed Pfizer's withdrawal of the revocation action and the counterclaim for revocation concerning GlaxoSmithKline's EP 4 183 412 (RSV vaccine patent), allowing GSK to withdraw its corresponding patent amendment application. Proceedings were declared closed. Each party bears its own costs. The request for 60% court fee reimbursement was allowed.
2024-07-31UPC_CFI_195/2024The Hague LDApplication for provisional measures—PI grantedThe Hague Local Division granted a preliminary injunction against the defendant prohibiting direct infringement of EP 1 993 350 B2 (relating to a hybrid Agaricus bisporus mushroom strain) in the Netherlands, Germany, France and Italy. The court held that the mushroom strain was not excluded from patentability under Art. 53(b) EPC and found a prima facie case of infringement. The defendant was ordered to deliver up infringing Cayene mushroom strains, provide customer information, pay an interim award of EUR 11,000 in costs, and penalties of up to EUR 50,000 per day for non-compliance. The injunction was made conditional on Amycel providing security of EUR 200,000.